quinta-feira, 5 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 16, 2026

Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica

View original at globenewswire.com
Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Total US cardiovascular deaths hit 931,578 with age-adjusted death rate rose to 233.3 per 100,000

    80% confidence
  • 127.9 million US adults had some form of cardiovascular disease in 2024

    80% confidence
  • A 2025 analysis identified 51 major cardiovascular clinical trials published between 2019 and 2024, enrolling a total of 292,985 patients

    80% confidence
  • Weekly procedure rates averaging 16,200 cases throughout 2024 for pulsed field ablation

    80% confidence
  • Medtronic's PulseSelect demonstrated an average skin-to-skin procedure time of just 36 minutes in 2024 with 98% of pulmonary veins remained isolated

    80% confidence
  • New clinical trial initiations surged by 68% in the decade ending 2024

    80% confidence
  • Boston Scientific's Farapulse procedures finished in under 90 minutes in 90% of cases, while thermal ablation only achieved this speed in 60% of cases

    80% confidence
  • 45% of global cath lab equipment exports originating from US manufacturers in 2024

    80% confidence
  • The global cardiovascular devices market size was valued at USD 74.58 billion in 2025 and is projected to hit the market valuation of USD 157.32 billion by 2035 at a CAGR of 7.70% during the forecast period 2026–2035

    80% confidence
  • 46% of US counties operate without a single practicing cardiologist, while 86% of rural counties lack access entirely

    80% confidence
  • As of December 2025, over 2,000 cardiovascular drugs and device-delivery therapies were in active development

    80% confidence
  • Varipulse achieved an 80% recurrence-free rate

    80% confidence
  • FDA cleared a record 39 new clinical AI algorithms in May 2025, bringing the total to 116 cleared cardiology algorithms

    80% confidence
  • North America secured the largest geographical portion, contributing 45.68% of the revenue share in 2025

    80% confidence
  • Average cost for a TAVR procedure in 2024 ranged from USD 52,176 in Chicago to USD 81,889 in California

    80% confidence
  • Nearly 12.1 million people in the US are projected to be diagnosed with Atrial Fibrillation by 2030

    80% confidence
  • Projected global healthcare cost savings from wearable adoption estimated at USD 200 billion over the next 25 years

    80% confidence
  • MANIFEST-17K study reported a 0% rate of esophageal damage and pericardial tamponade rate of just 0.36%

    80% confidence
  • Global shipments of wearable health devices reached 440 million units in 2024, with 160 million units specifically designated as medical sensors for clinical monitoring

    80% confidence
  • China accounted for 22.26% of the global cardiovascular disease burden

    80% confidence
  • The therapeutics & surgical devices category held a commanding position, accounting for a 77.5% revenue share in 2025

    80% confidence
  • Total surgical procedure volumes reached 18.9 million in 2024, with the United States and China accounting for 3.6 million and 3.5 million interventions, respectively

    80% confidence
  • UK cardiac waiting list swelling to 421,433 patients by May 2024 and Canadian wait times reaching 194 days

    80% confidence
  • Vascular device investment reaching USD 759 million and cardiovascular venture investment stabilizing at USD 542 million in 2024

    80% confidence
  • FDA listed 1,176 devices in its Breakthrough Device Program as of August 2024, with 243 designations specifically allocated to cardiovascular innovations

    80% confidence
  • Stroke caused 162,890 deaths in the US

    80% confidence
  • FDA cleared 16 distinct breakthrough cardiovascular devices in the 12 months leading up to August 2024

    80% confidence
  • The US supported 4,300 operational cardiac catheterization labs in 2024, while the number of hybrid cath labs globally reached 2,400

    80% confidence
  • 92% of US smartwatch users utilize their device primarily for health tracking, with 37% specifically monitoring heart metrics

    80% confidence
  • Funding for AI-integrated cath lab solutions rose by 20% in 2024

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · cardiology ai algorithms total116 algorithms
U.S. Food and Drug Administration · ai algorithms cleared may 202539 algorithms
U.S. Food and Drug Administration · cleared breakthrough cvd devices 12mo16 devices
U.S. Food and Drug Administration · breakthrough cardiovascular devices243 devices
U.S. Food and Drug Administration · breakthrough devices total1176 devices
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,549 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Cardiovascular Devices Market Projected to Reach US$ 157.32 Billion by 2035, Supported by Expanding Clinical Research Activity Says Astute Analytica — Source | Via News | pt.VIA.NEWS